← Evidence map

TrialHuman vaccines & immunotherapeutics2025

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.

María Jesús López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study. | OpenQuestion